Publications by authors named "Mac Wu"
Article Synopsis
- IGF1 is a key target in cancer therapy, and it binds to specific integrins, leading to important signaling through a ternary complex with IGF1R.
- A mutant form of IGF1 (R36E/R37E) that cannot bind to integrins inhibits normal signaling and competes with wild-type IGF1, reducing its effects on cell viability, particularly in anchorage-independent conditions.
- In experiments, R36E/R37E was shown to suppress tumor growth in vivo while wild-type IGF1 promoted it, suggesting R36E/R37E acts as a negative regulator of IGF1 signaling and could have therapeutic potential in cancer treatment.
